IP Library Granted Patent US 9,592,287
Granted Patent B2
US 9,592,287 · App. 12/897,997 · Granted Mar 14, 2017

Immunopotentiator-linked oligomeric influenza immunogenic compositions

Inventors: Shibo Jiang (Fresh Meadows, NY); Lanying Du (Rego Park, NY)
Assignee: New York Blood Center, Inc.
A61K39/145A61K39/12A61K39/385C12N7/00A61K2039/55516A61K2039/58A61K2039/6056C07K2319/30C12N2760/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,592,287
App. No.
12/897,997
Granted
Mar 14, 2017
Kind
B2
Abstract

Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator.

Claims (11)

1. An immunogenic composition for induction of an immune response against influenza virus comprising a fusion polypeptide comprising:

an immunogen sequence from an influenza virus;

an immunopotentiator sequence comprising the Fc fragment of human IgG, or a muramyl peptide;

and a stabilization sequence, wherein said stabilization sequence is foldon.

2. The immunogenic composition of claim 1 , wherein said immunogen sequence is a hemagglutinin sequence of said influenza virus.

3. The immunogenic composition of claim 1 , wherein said immunogen sequence is a neuraminidase sequence of an influenza virus.

4. The immunogenic composition of claim 1 , wherein said immunogen sequence is a membrane protein sequence of an influenza virus.

5. The immunogenic composition of claim 1 , wherein said fusion polypeptide is produced in a mammalian expression system.

6. The immunogenic composition of claim 2 , wherein said hemagglutinin sequence is a fragment of a hemagglutinin sequence selected from the group consisting of HA1 HA2 and RBD.

7. The immunogenic composition of claim 1 , wherein said fusion polypeptide is selected from the group consisting of HA1-Fd-hFc, HA-Fd-hFc, HA2-Fd-hFc, HA-RBD-Fd-hFc, and HA1+3-259-Fd-hFc.

8. The immunogenic composition of claim 1 , wherein said immunogenic composition further comprises an adjuvant.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2010
From: JIANG, SHIBO; DU, LANYING
To: NEW YORK BLOOD CENTER
Reel/Frame 025091/0538 →
Continuity (2)
Provisional Application 61250442 · Oct 9, 2009
Related Publication 20110086058A1 · Apr 14, 2011